Skip to main content
Fig. 2 | Journal of Ovarian Research

Fig. 2

From: Intravenous neutralization of vascular endothelial growth factor reduces vascular function/permeability of the ovary and prevents development of OHSS-like symptoms in rhesus monkeys

Fig. 2

Effects of VEGFA neutralization during COS cycles; ovarian vascular flow/volume. Serum progesterone (P4; a), ovarian blood volume (BV; b), and ovarian vascular rate of flow (VF; c) in control COS cycles and COS cycles + anti-VEGFA (Avastin) treatment pre-hCG (Avastin Pre) and post hCG (Avastin Post). Values observed during natural menstrual cycles in these same females (NC) are depicted as a reference. For details of treatments see Materials and Methods. Upper case letters indicate differences (P < 0.05) between COS treatment groups at mid-luteal phase and lower case letters indicate differences (P < 0.05) within each treatment group between ovulation and mid-luteal phase

Back to article page

Journal of Ovarian Research

ISSN: 1757-2215

Contact us